MeCP2 links heterochromatin condensates and neurodevelopmental disease.

Autor: Li CH; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Coffey EL; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Dall'Agnese A; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Hannett NM; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Tang X; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Henninger JE; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Platt JM; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Oksuz O; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Zamudio AV; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Afeyan LK; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Schuijers J; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands., Liu XS; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York, NY, USA., Markoulaki S; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Lungjangwa T; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., LeRoy G; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA., Svoboda DS; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Wogram E; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Lee TI; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Jaenisch R; Whitehead Institute for Biomedical Research, Cambridge, MA, USA. jaenisch@wi.mit.edu.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. jaenisch@wi.mit.edu., Young RA; Whitehead Institute for Biomedical Research, Cambridge, MA, USA. young@wi.mit.edu.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. young@wi.mit.edu.
Jazyk: angličtina
Zdroj: Nature [Nature] 2020 Oct; Vol. 586 (7829), pp. 440-444. Date of Electronic Publication: 2020 Jul 22.
DOI: 10.1038/s41586-020-2574-4
Abstrakt: Methyl CpG binding protein 2 (MeCP2) is a key component of constitutive heterochromatin, which is crucial for chromosome maintenance and transcriptional silencing 1-3 . Mutations in the MECP2 gene cause the progressive neurodevelopmental disorder Rett syndrome 3-5 , which is associated with severe mental disability and autism-like symptoms that affect girls during early childhood. Although previously thought to be a dense and relatively static structure 1,2 , heterochromatin is now understood to exhibit properties consistent with a liquid-like condensate 6,7 . Here we show that MeCP2 is a dynamic component of heterochromatin condensates in cells, and is stimulated by DNA to form liquid-like condensates. MeCP2 contains several domains that contribute to the formation of condensates, and mutations in MECP2 that lead to Rett syndrome disrupt the ability of MeCP2 to form condensates. Condensates formed by MeCP2 selectively incorporate and concentrate heterochromatin cofactors rather than components of euchromatic transcriptionally active condensates. We propose that MeCP2 enhances the separation of heterochromatin and euchromatin through its condensate partitioning properties, and that disruption of condensates may be a common consequence of mutations in MeCP2 that cause Rett syndrome.
Databáze: MEDLINE
Externí odkaz: